Publications:

Targeting AKT and CK2 represents a novel therapeutic strategy for SMO constitutive activation-driven medulloblastoma.

Cns Neuroscience & Therapeutics

Yao, Yue-Liang YL; Wang, Yan-Xia YX; Yang, Fei-Cheng FC; Wang, Chuan C; Mao, Min M; Gai, Qu-Jing QJ; He, Jiang J; Qin, Yan Y; Yao, Xiao-Xue XX; Lan, Xi X; Zhu, Jiang J; Lu, Hui-Min HM; Zeng, Hui H; Yao, Xiao-Hong XH; Bian, Xiu-Wu XW; Wang, Yan Y

Publication Date: 2022-07

Variant appearance in text: PC: M810T

PubMed Link: 35419951

Variant Present in the following documents:

• CNS-28-1033-s002.pdf

View BVdb publication page